In 2016, the Kigali Amendment to the Montreal Protocol set a clear global ambition to phase down the use of hydrofluorocarbons (HFCs) and reduce their environmental ...

Sue Tabbitt elicits some predictions for the year ahead from industry experts. AI will inevitably feature heavily again, but in what context - and where else shou...

An interview with Brian Morrissey, General Manager of Gaelic Laboratories, about the recent deal that put all of Ireland’s Beta-Lactam manufacturing capacity under o...

International Pharmaceutical Industry journal speaks with Symeres’ Chief Commercial Officer, Philip Payne, and Head of Drug Development, Goran Verspui, on the compan...

Sue Tabbitt, senior writer at Sarum Life Sciences reflects on a tumultuous year for technology strategy delivery in life sciences. 2025 has been a trying year...

International Pharmaceutical Industry journal speaks with CurTec’s John Jansen, Head of Global Marketing, and Marc Martens, Marketing Communications Manager, on ...

Small molecules have been around for decades; are they still central to your strategy? Absolutely. Small molecules remain central to our strat...